Browsing: Actinium Pharmaceuticals

–       Two oral presentations and three poster presentations will highlight Iomab-B and Iomab-ACT CD45 targeted conditioning for bone marrow transplant…

NEW YORK, June 16, 2023 /PRNewswire/ — Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in…

–  Iomab-B met the primary endpoint of durable Complete Remission (dCR) of 6-months following initial complete remission after BMT with…